I'm very eagerly awaiting detailed results on the DurAVR in humans but they will likely not be published until quite some time in the future.
After we got the interim results for the 5 patients, I sent a massive email to Anteris IR asking questions about the results and for more information about their relationship to the studies footnoted in the press release. IR was nice, as they always are, and tried to be helpful but at this point they understandably can't offer more than what was publicly released. Right now what we have are studies on CardioCel and the ADAPT technology.
It is interesting that in the study we are discussing there is the implication that the calcification and degeneration of the CardioCel patches in the one patient could have been a result of poor hemodynamics that resulted from an improper procedure and using CardioCel patches as a repair is obviously much different that ADAPT tissue in the DurAVR, where restoring hemodynamics to some level of normalcy is very possible or probable.
AVR Price at posting:
$23.42 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)